Zhi Tong Cai Jing·2025-10-14 11:13Core Viewpoint - Fosun Pharma (02196) announced that its subsidiary, Fosun Wanguo (Jiangsu) Pharmaceutical Group Co., Ltd., has received notification from the National Medical Products Administration (NMPA) regarding the withdrawal of the registration application for the drug Dihydrosuccinimide Ruxolitinib Capsules (project code: SAF-189) [1] Group 1 - The drug is an innovative small molecule chemical drug primarily intended for the treatment of non-small cell lung cancer (ALK+) and non-small cell lung cancer (ROS1+) [1] - The registration application for this drug for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) positivity was accepted by the NMPA in March 2025 [1] - The withdrawal of the registration application does not signify the termination of the project; Fosun Wanguo will enhance the registration materials according to the latest technical requirements from the NMPA and will resubmit the application as soon as possible [1] Group 2 - The withdrawal of the registration application is not expected to have a significant impact on the current performance of the group (including the company and its subsidiaries) [1]